Evidence map›Paper›PMID 41965346›Full record

ArticleNature communications2026

Boosting pathology foundation models via few-shot prompt-tuning for rare cancer subtyping.

Dexuan He, Xiao Zhou, Wenbin Guan, Liyuan Zhang, Xiaoman Zhang, Sinuo Xu, Ge Wang, Lifeng Wang, Xiaojun Yuan, Jing Ma and 5 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Dexuan He *School of Artificial Intelligence, Shanghai Jiao Tong University, Shanghai, China.ORCID http://orcid.org/0009-0009-2541-609X
Xiao Zhou *Shanghai Artificial Intelligence Laboratory, Shanghai, China.ORCID http://orcid.org/0000-0001-5121-5640
Wenbin Guan *Department of Pathology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Liyuan ZhangSchool of Artificial Intelligence, Shanghai Jiao Tong University, Shanghai, China.
Xiaoman ZhangDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7696-9366
Sinuo XuSchool of Artificial Intelligence, Shanghai Jiao Tong University, Shanghai, China.
Ge WangDepartment of Oral Pathology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0001-8097-6318
Lifeng WangDepartment of Pathology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaojun YuanDepartment of Pediatric Hematology/Oncology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jing MaDepartment of Pathology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xin SunClinical Research and Innovation Unit, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yanfeng WangSchool of Artificial Intelligence, Shanghai Jiao Tong University, Shanghai, China.ORCID http://orcid.org/0000-0002-3196-2347
Kun SunDepartment of Pediatric Cardiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. sunkun@xinhuamed.com.cn.ORCID http://orcid.org/0000-0002-0504-7372
Ya ZhangSchool of Artificial Intelligence, Shanghai Jiao Tong University, Shanghai, China. ya_zhang@sjtu.edu.cn.ORCID http://orcid.org/0000-0002-5390-9053
Weidi XieSchool of Artificial Intelligence, Shanghai Jiao Tong University, Shanghai, China. weidi@sjtu.edu.cn.ORCID http://orcid.org/0009-0002-8609-6826

Funding

China Postdoctoral Science Foundation 2023M741850National Natural Science Foundation of China (National Science Foundation of China) No. 24Z031503678
6 · The paper itself

Abstract

Rare cancers comprise 20-25% of malignancies (over 70% in pediatric oncology) but face major diagnostic challenges due to limited expert availability. While pathology vision-language models show promising zero-shot capabilities for common cancers, their performance on rare cancers remains limited. Existing multi-instance learning (MIL) methods rely solely on visual features, overlooking cross-modal knowledge and compromising interpretability critical for rare cancer diagnosis. To address this, we propose PathPT, a framework that exploits vision-language foundation models through spatially-aware visual aggregation and task-specific prompt tuning. PathPT converts WSI-level supervision into fine-grained tile-level guidance, preserving tumor localization and enabling cross-modal reasoning. Across eight rare and three common cancer datasets-spanning 56 subtypes and 3958 WSIs, PathPT consistently outperforms state-of-the-art methods under data-scarce settings. It achieves substantial gains in both subtyping accuracy and cancerous region grounding ability, providing a scalable, interpretable AI solution to improve rare cancer subtyping with limited access to specialized expertise.

Indexed as

NeoplasmsRare DiseasesHumansMultiple-Instance Learning Algorithms

Identifiers

PMID41965346
PMCPMC13243476

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.